REPLIGEN CORP(RGEN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,016 of 2,961 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RGEN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for REPLIGEN CORP (RGEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RGEN at 58.4/100 on a 32-signal composite quality model, placing it at rank #1,016 of 2,961 stocks — the top half of the AI-ranked universe. RGEN scores in the top quartile across earnings quality (91.3). Areas of concern include institutional flow (37.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), REPLIGEN CORP reports quarterly revenue of $204.1M, net income of $5.0M, an operating margin of 6.9%. Top institutional holders of RGEN by reported 13-F value include BlackRock, FMR, UNITED CAPITAL FINANCIAL ADVISORS, based on the most recent SEC filings. RGEN trades on the Nasdaq exchange and files with the SEC under CIK 730272. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REPLIGEN CORP directly from SEC EDGAR. REPLIGEN CORP's 13F Pro composite quality score has ranged between 35 and 68 since 2023, currently 58.4 — a declining long-term trajectory across 59 quarterly and live scoring snapshots.
Revenue
Q2 2026
$204.1M
Net Income
Q2 2026
$5.0M
Free Cash Flow
Q2 2026
$27.4M
Operating Margin
Q2 2026
6.9%
ROIC
Q2 2026
2.1%
D/E Ratio
Q2 2026
0.26
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+16.4% YoYNet Income
+291.6% YoYOperating Income
+257.1% YoYEPS (Diluted)
+287.0% YoYTotal Assets
+4.2% YoYTotal Debt
+3.2% YoYOp. Cash Flow
-33.1% YoYFree Cash Flow
-37.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $738.3M +16.4% | $634.4M +0.3% | $632.4M -21.1% | $801.5M +19.5% | $670.5M +83.1% | $366.3M |
| Net Income | $48.9M +291.6% | $-25.5M -171.7% | $35.6M -80.9% | $186.0M +45.0% | $128.3M +114.1% | $59.9M |
| Operating Income | $55.2M +257.1% | $-35.1M -173.6% | $47.7M -78.8% | $224.7M +34.3% | $167.2M +139.5% | $69.8M |
| EPS (Diluted) | $0.86 +287.0% | $-0.46 -173.0% | $0.63 -80.6% | $3.24 +44.6% | $2.24 +101.8% | $1.11 |
| Total Assets | $2.95B +4.2% | $2.83B -0.1% | $2.83B +11.8% | $2.53B +7.3% | $2.36B +23.9% | $1.90B |
| Total Debt | $542.2M +3.2% | $525.6M | — | — | — | — |
| Operating Cash Flow | $117.4M -33.1% | $175.4M +54.0% | $113.9M -33.8% | $172.1M +44.6% | $119.0M +90.0% | $62.6M |
| Free Cash Flow | $93.9M -37.3% | $149.7M +92.7% | $77.7M -10.9% | $87.2M +68.0% | $51.9M +29.3% | $40.2M |
Get alerted when RGEN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for REPLIGEN CORP including:
Top Institutional Holders of RGEN
BlackRock, Inc.
$734.7M5,384,938 shFMR LLC
$453.9M3,326,690 shUNITED CAPITAL FINANCIAL ADVISORS, LLC
$380.8M2,790,650 shVANGUARD CAPITAL MANAGEMENT LLC
$329.0M2,411,171 shVANGUARD PORTFOLIO MANAGEMENT LLC
$315.6M2,312,825 shMAVERICK CAPITAL LTD
$270.8M1,984,554 shSTATE STREET CORP
$245.7M1,800,530 shPRICE T ROWE ASSOCIATES INC /MD/
$239.1M1,752,274 shMASSACHUSETTS FINANCIAL SERVICES CO /MA/
$220.6M1,617,021 shWASATCH ADVISORS LP
$217.0M1,590,251 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $734.7M | 5,384,938 |
| FMR LLC | $453.9M | 3,326,690 |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | $380.8M | 2,790,650 |
| VANGUARD CAPITAL MANAGEMENT LLC | $329.0M | 2,411,171 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $315.6M | 2,312,825 |
| MAVERICK CAPITAL LTD | $270.8M | 1,984,554 |
| STATE STREET CORP | $245.7M | 1,800,530 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $239.1M | 1,752,274 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $220.6M | 1,617,021 |
| WASATCH ADVISORS LP | $217.0M | 1,590,251 |
Companies Similar to RGEN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
iRhythm Holdings, Inc.
BIO-TECHNE Corp
HAEMONETICS CORP
LifeStance Health Group, Inc.
MERIT MEDICAL SYSTEMS INC
Lantheus Holdings, Inc.
HALOZYME THERAPEUTICS, INC.
Vericel Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put RGEN on your watchlist
Track score changes the day REPLIGEN CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RGEN a good stock to buy?
13F Pro's AI-powered analysis of REPLIGEN CORP (RGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RGEN are available on the RGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RGEN is classified as a mid company.
Which hedge funds own RGEN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REPLIGEN CORP's investment landscape.